Startup aims to churn out other orphan drug startups

04/25/2013 | Xconomy

Armed with $16 million in venture capital, former MedImmune boss David Mott's new enterprise Cydan will find and fund small firms with promising orphan drug candidates. Investor return will be through licensing deals with or acquisition by larger drugmakers. Mott plans to collaborate with parent and patient advocacy groups and will subcontract toxicology, pharmacology and other testing to reduce development risk.

View Full Article in:

Xconomy

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Payer Marketing
Avalere Health
Washington, DC
Chief Quality Officer
UnityPoint Clinic
Des Moines, ID
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX
The Pew Charitable Trusts
Director, Antibiotics and Innovation Project
Washington, DC
Senior Officer, Drugs and Medical Devices
The Pew Charitable Trusts
Washington, DC